GW420867X Administered to HIV-1-Infected Patients Alone and in Combination with Lamivudine and Zidovudine

REFERENCES

• Kleim J-P, Bender R, Billhardt UM, et al. Activity of a novel quinoxaline derivative against human immunodeficiency virus type 1 reverse transcriptase and viral replication. Antimicrob Agents Chemother. 1993;37:1659–1664.
   PubMed Web of Science ®Google Scholar
• Kleim J-P, Winters M, Dunkler A, et al. Antiviral activity of the human immunodeficiency virus type 1 specific nonnucleoside reverse transcriptase inhibitor HBY097 alone and in combination with zidovudine in a phase II study. J Infect Dis. 1999;179:709–713.
   PubMed Web of Science ®Google Scholar
• Balzarini J, De Clercq E, Carbonez A, Burt V, Kleim J-P. Long-term exposure of HIV type 1-infected cell cultures to combinations of the novel quinoxaline GW420867X with lamivudine, abacavir, and a variety of nonnucleoside reverse transcriptase inhibitors. AIDS Res Hum Retroviruses. 2000;16:517–528.
   PubMed Web of Science ®Google Scholar
• Prince VVT, Moore KHP, Cass L, et al. GW420867X, a new non-nucleoside reverse transcriptase inhibitor (NNRTI) - initial phase evaluation. Antiviral Res. 1999;41:A48.
   Google Scholar
• Moore KHP, Cass L, Dallow N, Jones A, Prince WT, Sisson J. Effect of high fat and normal meals on the relative bioavailabillity of GW420867X 100 mg administered as a single oral dose to healthy volunteers. In: Program and abstracts of the 39th Inter science Conference in Antimicrobial Agents and Chemotherapy; September 26–29, 1999; San Francisco, CA. Abstract 332.
   Google Scholar
• Larder BA, Kemp SD, Harrigan PR. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science. 1995;269:696–699.
   PubMed Web of Science ®Google Scholar
• Kellam P, Larder B. Recombinant virus assay: A rapid, phenotypic assay for assessment of drug susceptibility of human immunodeficiency virus type 1 isolates. Antimicrob Agents Chemother. 1994;38:23–30.
   PubMed Web of Science ®Google Scholar
• Corbett JW, Ko SS, Rodgers JD, et al. Expanded-spectrum nonnucleoside reverse transcriptase inhibitors inhibit clinically relevant mutant variants of human immunodeficiency virus type 1. Antimicrob Agents Chemother. 1999;43: 2893–2897.
   PubMed Web of Science ®Google Scholar
• Tisdale M, Kemp S, Parry NR, Larder B. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to ′-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc Natl Acad Sc/ USA. 1993;90:5653–5656.
   PubMed Web of Science ®Google Scholar
• Zhang H, Vrang L, Backbro K, et al. Inhibition of human immunodeficiency virus type 1 wild-type and mutant reverse transcriptase by the phenyl ethyl thiozolyl thiourea derivatives trovirdine and MSG-127. Antiviral Res. 2000;28:331–342.
   Web of Science ®Google Scholar
• Staszewski S, Morales-Ramirez J, Tashima KT, et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. N Engl J Med. 2000;341:1865–1873.
   Web of Science ®Google Scholar
• Pollard RB, Robinson P, Dransfield K. Safety profile of nevirapine, a nonnucleoside reverse transcriptase inhibitor for the treatment of human immunodeficiency virus infection. Clin Ther. 1998;20:1071–1092.
   PubMed Web of Science ®Google Scholar
• Friedland GH, Pollard R, Griffith B, et al. Efficacy and safety of delavirdine mesylate with zidovudine and didanosine compared with two-drug combinations of these agents in persons with HIV disease with CD4 counts of 100 to 500 cells per cubic millimetre (ACTG 261). J Acquired Immune Defic Syndr. 1999;21:281–292.
   PubMed Web of Science ®Google Scholar
• D'Aquila R, Hughes MD, Johnson VA, et al. Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection. Ann Inter Med. 1996;124:1019–1030.
   PubMed Web of Science ®Google Scholar
• Davey RT, Chaitt DG, Reed GF, et al. Randomized, controlled phase I/II trial of combination therapy with delavirdine (U-901525) and conventional nucleosides in human immunodeficiency virus type 1-infected patients. Antimicrob Agents Chemother. 1996;40:1657–1664.
   PubMed Web of Science ®Google Scholar
• de Jong MD, Vella S, Carr A, et al. High dose nevirapine in previously untreated human immunodeficiency virus type 1-infected persons does not result in sustained suppression of viral replication. J Infect Dis. 1997;175:966–970.
   PubMed Web of Science ®Google Scholar
• Floridia M, Bucciardini R, Ricciardulli D, et al. A randomized, double-blind trial on the use of a triple combination including nevirapine, a nonnucleoside reverse transcriptase HIV inhibitor, in antiretroviral-naive patients with advanced disease. J Acquired Immune Defic Syndr. 1999;20:11–19.
   Web of Science ®Google Scholar
• Moore KHP, Cass L, Kapoor A, et al. GW420867X, a new non-nucleoside reverse transcriptase inhibitor (NNRTI), repeat dose pharmacokinetics and single rising dose pharmacokinetics (PK). In: Program and abstracts of the 6th Conference on Retroviruses and Opportunistic Infections; January 31-February 4, 1999; Chicago, Illinois. Abstract 601.
   Google Scholar
• Kleim J-P, Burt V, Maguire M, Mutch P, Hazen RJ, St Clair M. GW420867X: A novel quinoxalineclass NNRTI of HIV-1 with improved antiviral properties in the presence of human serum and its components. In: Program and abstracts of the 6th Conference on Retroviruses and Opportunistic Infections; January 31-February 4, 1999; Chicago, Illinois. Abstract 599.
   Google Scholar
• Wang LH, Chittick GE, McDowell JA. Single-dose pharmacokinetics and safety of abacavir (1592U89), zidovudine, and lamivudine administered alone and in combination in adults with human immunodeficiency virus infection. Antimicrob Agents Chemother. 1999;43:1708–1715.
   PubMed Web of Science ®Google Scholar
• Richman D, Havlir D, Corbeil J, et al. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. J ViroL 1994;68:1660–1666.
   PubMed Web of Science ®Google Scholar
• Moxham CP, Banke-Bochita J, Fuder H, et al. A dose ranging study to evaluate the efficacy and safety of M KC-442 in HIV-infected patients. In: Program and abstracts of the 6th European Conference on Clinical Aspects and Treatment of HIV-Infection; October 11–15, 1997; Hamburg, Germany.
   Google Scholar